Daijiworld Media Network - New Delhi
New Delhi, Nov 19: The Centre has proposed bringing antimicrobial medicines under the central regulatory framework applicable to new drugs to strengthen oversight of their quality, safety and efficacy and tackle the growing threat of antimicrobial resistance (AMR).
The Union Health Ministry has proposed amendments to the New Drugs and Clinical Trials Rules, 2019, through a draft gazette notification dated November 6. The proposed changes seek to include antimicrobials within the definition of a new drug under Rule 2(1)(w)(v).
A Union Health Ministry official said the amendment was initiated amid concerns that manufacturing licences for antimicrobial products were being granted without adequate regulatory scrutiny, including mandatory assessments such as bioavailability and bioequivalence studies and stability studies.

Officials warned that the absence of such assessments could compromise the quality, safety and effectiveness of antimicrobial products. Substandard or ineffective medicines could contribute to the development and spread of antimicrobial resistance, posing serious risks to patient safety.
Under the proposed framework, manufacturers would be required to obtain prior permission from the Central Licensing Authority (CLA) before approaching the respective State Licensing Authority (SLA) for a manufacturing licence.
The move is expected to strengthen central regulatory oversight and ensure that antimicrobial products undergo appropriate scientific and quality assessments before new manufacturing licences are granted.
However, manufacturing licences already issued will remain valid under the proposed amendment. Existing licence holders will not be required to seek fresh permission from the Central Licensing Authority, officials clarified.
Antimicrobials are substances that kill microorganisms or prevent their growth. They include medicines used to treat or prevent infections caused by bacteria, viruses, fungi and parasites, as well as substances applied to the skin and surfaces to reduce microbial contamination.
Antimicrobial resistance occurs when microorganisms evolve and develop the ability to withstand medicines that were previously effective against them. This makes infections increasingly difficult to treat, raises the risk of disease complications and deaths, and places additional pressure on healthcare systems.
The World Health Organisation (WHO) has identified AMR as one of the top global public health threats, warning that drug-resistant infections could undermine the effectiveness of modern medical treatments.
The Union Health Ministry has emphasised that tackling AMR requires coordinated action across human health, animal health, agriculture and the environment through the One Health approach.
The G20 New Delhi Leaders' Declaration also highlighted the importance of addressing antimicrobial resistance through this coordinated approach.
The proposed amendment is part of the government's broader efforts to promote the responsible use of antimicrobial medicines, strengthen pharmaceutical quality standards and protect patients from ineffective or substandard products.
The draft notification has invited objections and suggestions from stakeholders and members of the public before the proposed changes are finalised.
The development coincides with World Antimicrobial Resistance Awareness Week (WAAW), observed from November 18 to 24, to raise awareness about drug-resistant infections and encourage responsible use of antimicrobial medicines.